SCHEMBL596476

SCHEMBL596476

CCOC(=O)N1CCC(Nc2ncc(N)cn2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.54
CDK1 P06493 3/20 0.54
CDK4 P11802 3/20 0.54
CCND1 P24385 3/20 0.54
NOS2 P35228 5/20 0.51
NOS1 P29475 4/20 0.49
NOS3 P29474 2/20 0.49
CCNA2 P20248 1/20 0.48
CCNA1 P78396 1/20 0.48
MAP4K4 O95819 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CCNK O75909 2/20 0.47
CDK12 Q9NYV4 2/20 0.47
TSHR P16473 1/20 0.45
MAPK8 P45983 1/20 0.45
MAPK9 P45984 1/20 0.45
MAPK10 P53779 1/20 0.45
THRB P10828 1/20 0.45
ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL596475 1.00 CDK2 (0.54) CDK2CDK1CDK4CCND1NOS2
SCHEMBL595392 0.87 NOS2 (0.59) CDK2CDK1CDK4CCND1NOS2
SCHEMBL595393 0.87 NOS2 (0.59) CDK2CDK1CDK4CCND1NOS2
SCHEMBL595030 0.84 USP30 (0.53) L3MBTL1
SCHEMBL595029 0.84 USP30 (0.53) L3MBTL1
SCHEMBL596621 0.81 MAPT (0.54) NOS2NOS1NOS3MAP4K4KDM4E
SCHEMBL596620 0.81 MAPT (0.54) NOS2NOS1NOS3MAP4K4KDM4E
SCHEMBL3773857 0.80 NOS2 (0.59) CDK2CDK1CDK4CCND1NOS2
SCHEMBL3776029 0.78 NOS2 (0.74) CDK2CDK1CDK4CCND1NOS2
SCHEMBL12780763 0.77 NOS2 (0.55) CDK2CDK1CDK4CCND1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153644-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-04-10 US disclosed
US-8115011-B2 (S)-3-{5-[(1-Pyridin-2-yl-3-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-ylamino}-pyrrolidine-1-carboxylic acid ethyl ester; obesity, type II diabetes mellitus and metabolic syndrome MADRIGAL PHARMACEUTICALS, INC. (US) 2012-02-14 US disclosed
US-8058299-B2 Diacylglycerol acyltransferase inhibitors VIA PHARMACEUTICALS, INC. (US) 2011-11-15 US disclosed
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-07-02 US disclosed
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-23 US disclosed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US disclosed
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT CDK2 1046/4885CDK1 2550/4885CDK4 3077/4885
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT CDK2 1046/4885CDK1 2550/4885CDK4 3077/4885
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT CDK2 1046/4885CDK1 2550/4885CDK4 3077/4885
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT CDK2 1046/4885CDK1 2550/4885CDK4 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.